Pediatric acute liver failure: variations in referral timing are associated with disease subtypes

Ekkehard Sturm1, Willem S Lexmond, Henkjan J Verkade

  • 1Pediatric Gastroenterology/Hepatology, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands, ekkehard.sturm@med.uni-tuebingen.de.

Insights

Referral timing in pediatric acute liver failure (PALF) varies with clinical presentation. Early recognition of prognostic indicators and subacute liver failure (SLF) can improve PALF management.

Area of Science:

  • Pediatric Hepatology
  • Liver Transplantation
  • Acute Liver Failure

Background:

  • Rapid referral to a transplant center is crucial in pediatric acute liver failure (PALF).
  • Clinical variability in PALF can impact the timing of referrals.
  • Understanding referral patterns is key to optimizing patient management.

Purpose of the Study:

  • To analyze the relationship between early or late referral timing and clinical characteristics in PALF.
  • To investigate the impact of referral timing on patient outcomes.
  • To identify factors associated with delayed referrals in PALF.

Main Methods:

  • Retrospective, single-center comparative analysis of two PALF cohorts (early vs. late referral).
  • Evaluation of clinical parameters, liver function tests, and prognostic indicators.
  • Multivariate analysis to identify independent predictors of referral timing.

Main Results:

  • Early referrals were associated with non-icteric presentation, lower hepatic encephalopathy grades, and lower bilirubin levels.
  • Early referred patients had higher alanine aminotransferase (ALAT) levels and fewer poor prognostic indicators.
  • Subacute liver failure (SLF) was independently associated with late referral.

Conclusions:

  • Referral timing in PALF is linked to specific clinical and biochemical profiles.
  • Early identification of prognostic signs and SLF is essential for timely referrals.
  • Improving referral timing may enhance overall PALF management strategies.
Abstract

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
405
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
954
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
400
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
380
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
547